News & Perspective

Oct 05, 2012

Nov 09, 2012

Nov 09, 2012

BioCryst may drop quest for US approval of peramivir

(CIDRAP News) – BioCryst Pharmaceuticals Inc. signaled yesterday it will probably give up on seeking a US license for the influenza drug peramivir, a move that would reduce the already limited options for severely ill flu patients in need of an intravenous antiviral drug.

Pages

Sort Results By:

 Sort Results By:

Narrow results by:

by country

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3MAccelerate DiagnosticsGilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»